CHCHD10 mutations and motor neuron disease: the distribution in Finnish patients.

Penttilä, Sini

2017


http://hdl.handle.net/10138/233790
https://doi.org/10.1136/jnnp-2016-314154

Downloaded from Helda, University of Helsinki institutional repository.
This is an electronic reprint of the original article.
This reprint may differ from the original in pagination and typographic detail.
Please cite the original version.
INTRODUCTION

Motor neuron disorders (MNDs) are a heterogeneous group of diseases that result from degeneration of motor neurons. If both upper and lower motor neurons (UMNs and LMNs) are affected, the disease is classified as amyotrophic lateral sclerosis (ALS). Primary lateral sclerosis (PLS) and progressive muscular atrophy (PMA) selectively affect the UMN or LMN, respectively, but are sometimes considered to be incomplete ALS variants because their phenotype may evolve into typical ALS over time. Bulbar affection in a UMN disease would favour a diagnosis of PLS over hereditary spastic paraplegia (HSP), whereas rapid progression may separate PMA from adult-onset spinal muscular atrophy (SMA).

Some SMA-like or even ALS-like phenotypes have been incorporated into the large category of sensorimotor axonal neuropathies (Charcot-Marie-Tooth disease type 2, CMT2), although sensory abnormalities may be subtle in some forms. On the other hand, spinal and bulbar muscular atrophy (Kennedy disease) is classified as a form of adult-onset SMA despite prominent sensory abnormalities. It has recently been argued that the current classification system of MNDs is unsatisfactory and should be revised to include genetically and prognostically important categories.

We have recently identified a new form of motor neuron disease in 53 patients from 17 Finnish families, where distinctive phenotype did not match any pre-existing neuromuscular disease category. Spinal muscular atrophy Jokela type (SMAJ) is characterised by painful cramps, fasciculations, decreased or absent tendon reflexes, elevated creatine kinase, and hand tremor. The first symptoms appear commonly after age 30–40. Electromyography (EMG) and muscle biopsy display widespread neurogenic findings and a proportion of patients show sensory abnormalities. Muscle weakness and atrophy appear much later in the disease course, and patients have remained ambulant for several decades and their life expectancy is within normal range. SMAJ is caused by a dominant CHCHD10 mutation c.197G>T p.G66V, a founder mutation in the Finnish population. All Finnish patients reported c.197G>T p.G66V SMAJ6 or CMT2. However, the pathogenicity of most of the reported mutations has remained uncertain because the segregation has not been proven and/or functional studies have not been available. So far, most CHCHD10 studies have been concentrated on patients with ALS, although other phenotypes, such as SMAJ, seem to be more prevalent among the ascertained mutations.

Although CHCHD10 is a mitochondrial protein and other mutations in CHCHD10 have been reported to be associated with mitochondrial myopathy, no significant mitochondrial muscle pathology has been detected in patients with SMAJ. However, in a Finnish cohort of 126 families referred with CMT2 diagnosis, 4.8% had the c.197G>T p.G66V mutation and low levels of mitochondrial DNA (mtDNA) deletions were suspected in some.

In this study, we screened several cohorts of Finnish patients with distinct neurogenic disorders and one cohort of mitochondrial myopathy in order to clarify the prevalence of CHCHD10 mutations as well as their phenotypic manifestations. To further study the possible mtDNA instability due to c.197G>T p.G66V mutation, we compared the amount of mtDNA deletions in 10 patients with SMAJ to that of 9 patients with other genetically confirmed MNDs.

METHODS

Patients

Three hundred and thirty six Finnish patients with distinct neurogenic disorders and one cohort of mitochondrial myopathy were examined for signs of CHCHD10. Of the patients included in the study, 215 had lower motor neuron syndrome (LMNS) similar to SMAJ, with or without some sensory abnormalities. Five of these patients had an initial clinical diagnosis of CMT2 but with atypical features more suggestive of SMAJ, such as normal compound muscle action potential (CMAP) values despite widespread neurogenic abnormalities, or prominent creatine kinase elevations up to 1800 U/L. Of the other patients, 28 had HSR, 24 patients had a non-specified neurogenic disorder, 14 patients had mitochondrial myopathy and 55 patients had a diagnosis of ALS according to the El Escorial criteria with involvement of distinct phenotypes such as c.176C>T p.S59L causing frontotemporal dementia (FTD)-ALS with mitochondrial myopathy, c.172G>C p.G58R isolated mitochondrial myopathy and c.197G>T p. G66V SMAJ or CMT2. However, the pathogenicity of most of the reported mutations has remained uncertain because the segregation has not been proven and/or functional studies have not been available. So far, most CHCHD10 studies have been concentrated on patients with ALS, although other phenotypes, such as SMAJ, seem to be more prevalent among the ascertained mutations.

Although CHCHD10 is a mitochondrial protein and other mutations in CHCHD10 have been reported to be associated with mitochondrial myopathy, no significant mitochondrial muscle pathology has been detected in patients with SMAJ. However, in a Finnish cohort of 126 families referred with CMT2 diagnosis, 4.8% had the c.197G>T p.G66V mutation and low levels of mitochondrial DNA (mtDNA) deletions were suspected in some.

In this study, we screened several cohorts of Finnish patients with distinct neurogenic disorders and one cohort of mitochondrial myopathy in order to clarify the presence of CHCHD10 mutations as well as their phenotypic manifestations. To further study the possible mtDNA instability due to c.197G>T p.G66V mutation, we compared the amount of mtDNA deletions in 10 patients with SMAJ to that of 9 patients with other genetically confirmed MNDs.
UMN and LMN. Clinical features of the patient cohorts are presented in table 1.

In the patients with ALS, mutations in SOD1 and FUS as well as the repeat expansion mutation in C9orf72 had been previously excluded. For 23 of the patients with ALS, TARDBP had also been sequenced with normal findings. For patients with HSP, 33 known disease genes were screened by targeted next-generation sequencing panel prior to this study (as described in Ylikallio et al), without causative findings. The possible family history of the patients was not clarified before the study. The studies were approved by local ethical committees and all samples were obtained with informed consent.

### Molecular genetic analyses

Genomic DNA was extracted from venous blood according to standard procedures. For all patients, we sequenced exon 2 of CHCHD10 that harbours all pathogenic mutations reported so far. Additionally, in 103 patients, the rest of the coding region of the gene was also sequenced. Of these patients, 79 belonged to the LMNS group, 2 had mitochondrial myopathy, 15 had a non-specific neurogenic disorder and 7 had ALS. Primer sequences of the exons studied were designed to include the entire exon and exon–intron borders and are available on request. The regions studied were amplified by PCR (Thermo Scientific Fermentas PCR Master Mix; MBI Fermentas, Amherst, New York, USA) and directly sequenced using a Big-Dye Terminator V3.1 Kit on an ABI3130xl automatic DNA Genetic Analyzer (Applied Biosystems, Foster City, California, USA). Sequences were analysed with Sequencher V5.1 software (Gene Codes Corporation, Ann Arbor, Michigan, USA). For patients with HSP, the sequencing was done as described in Auranen et al.

### MtDNA analysis

For analysis of mtDNA deletions, we selected 10 patients with previously proven SMAJ and 9 patients with other genetically defined MNDs. Mitochondrial pathology on a light microscopic level was minor (1–2% COX-negative fibres) in the patients with SMAJ and only present in half (5/10) of the muscle biopsies. The group of other genetically defined MNDs consisted of three patients with ALS-FTD caused by C9orf72 repeat expansion mutation (two with minimal mitochondrial pathology, one without), five patients with Kennedy disease (two with minimal mitochondrial pathology, three without) and one patient with ALS caused by a homozygous c.272A>C p.D91A mutation in SOD1. The age of patients with SMAJ ranged from 41 to 57 years, whereas the ages of the other patients were from 39 to 62 years.

The DNA was extracted from muscle biopsies according to standard procedures. MtDNA deletion load was visualised by long-range PCR as described in Auranen et al.

### RESULTS

#### Genetic findings

Heterozygous mutation c.197G>T p.G66V in CHCHD10 was detected in 23 patients. In two siblings with a cramping disorder and mitochondrial pathology, heterozygous c.100C>T p.P34S was detected. Other mutations were not found.

#### MtDNA analysis

The results of mtDNA deletion analysis are presented in figure 1. The amount of deletions in SMAJ samples was very low and not higher than in the non-SMAJ samples. Furthermore, no obvious correlation between the amount of deletions and the ‘minor mitochondrial’ muscle phenotype of the patients was observed.

#### Clinical characteristics of the patients with CHCHD10 mutations

Patients carrying the mutation c.197G>T p.G66V had a slowly progressive, proximal and distal motor neuronopathy with reduced tendon reflexes. Age at onset ranged from 25 to

---

**Table 1** Patient cohorts included in the study

<table>
<thead>
<tr>
<th>Disorder</th>
<th>Number of patients</th>
<th>Clinical features</th>
</tr>
</thead>
<tbody>
<tr>
<td>LMNS</td>
<td>215</td>
<td>Predominantly lower motor neuron disease, including patients with atypical CMT2 (SMAJ-like phenotype)</td>
</tr>
<tr>
<td>ALS</td>
<td>55</td>
<td>Signs of UMN and LMN involvement</td>
</tr>
<tr>
<td>Non-specific</td>
<td>24</td>
<td>Cramp-fasciculation syndrome, no widespread weakness, neurogenic findings on EMG and/or muscle biopsy</td>
</tr>
<tr>
<td>neurogenic</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HSP</td>
<td>28</td>
<td>No signs of LMN involvement</td>
</tr>
<tr>
<td>Mitochondrial</td>
<td>14</td>
<td>Muscle histology compatible with mitochondrial disease</td>
</tr>
<tr>
<td>myopathy</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

ALS, amyotrophic lateral sclerosis; CMT2, Charcot-Marie-Tooth disease type 2; EMG, electromyography; HSP, hereditary spastic paraplegia; LMN, lower motor neuron; UMN, upper motor neuron; mtDNA, mitochondrial DNA; SMAJ, spinal muscular atrophy Jokela type.

**Figure 1** The results of mtDNA deletion analysis in patient groups of four different MNDs. The 8 kb band represents the undeleted mtDNA. Smaller bands correspond to deleted mtDNA molecules. Low levels of mtDNA deletions were observed in all MNDs included in the study, meaning they are not a specific feature of SMAJ. mito+=presence of mitochondrial pathology in muscle biopsies, mito-=absence of mitochondrial pathology in muscle biopsies, age=age of the patient at muscle biopsy, H2O=non-template PCR. MND, motor neuron disorder; mtDNA, mitochondrial DNA; SMAJ, spinal muscular atrophy Jokela type.
70 years, although one patient reported having always been clumsy (P20). In patient P5, the presenting symptom was reduced distal upper limb function, while in all others, lower limb symptoms predominated. The eldest patients, P2 and P3, still retained some ambulation at the ages of 82 and 86 years. Clinical characteristics of the patients are listed in Table 2.

Similar to our previous report, many patients had some reduction in sensory nerve action potential amplitudes (SNAPs), but this was extremely variable. For example, sural SNAPs were severely reduced in an otherwise asymptomatic 28-year-old woman (P12; 4.0 μV and −4.4 SD), while they were normal in a 79-year-old man (P2; 4.5 μV and −0.5 SD) with a disease duration of nearly two decades. In one patient (P8), all sensory amplitudes were severely reduced at the age of 57 (absent sural SNAPs with median, ulnar and radial SNAPs <1 μV), even though the clinical phenotype was typical of SMAJ with areflexia, muscle cramps in all limbs followed by slowly progressive weakness. In contrast to the reduced SNAP values in several patients, CMAP values were nearly always within normal range, although one patient has low amplitude CMAP values (P8; −2SD) in the upper and lower limbs. None of the patients developed severe foot drop despite very long disease durations of several decades. Lower limb muscle MRI in six patients showed fatty degenerative changes in the calves and posterior thigh muscles. Muscle biopsy obtained in nine patients displayed chronic neurogenic abnormalities with fibre type grouping and groups of normal sized type IIa fibres. Three out of 15 patients (P8, P17, P20) in this cohort showed fibrillations in the first dorsal interosseous muscle, which we previously have also shown to be very rare in SMAJ, as an important distinction from ALS.

Patients carrying c.100C>T p.P34S were siblings who had a cramping disorder with normal tendon reflexes and no neurogenic changes on EMG. Muscle biopsy findings suggested a mitochondrial myopathy. A third sibling with the same clinical and muscle pathology phenotype, however, did not carry the variant. The parents of the siblings were asymptomatic, but their DNA samples were not available for the study.

**DISCUSSION**

In our cohort of 336 Finnish patients with undetermined MND or mitochondrial myopathy, 23 proved to have the Finnish founder mutation c.197G>T p.G66V in **CHCHD10**. The phenotype of all of them was restricted to SMAJ. Previously, c.197G>T p.G66V mutation carriers have also been identified in a Finnish cohort of patients referred by the clinicians as having CMT2. There is growing evidence that dominantly

---

**Table 2** Clinical characteristics of the patients with heterozygous CHCHD10 mutation c.197G>T p.G66V

<table>
<thead>
<tr>
<th>Patient</th>
<th>Sex</th>
<th>Age at onset</th>
<th>Symptoms at onset</th>
<th>Age at examination</th>
<th>Inheritance</th>
<th>Walking ability</th>
<th>Neurography/electromyography abnormalities</th>
<th>CK</th>
</tr>
</thead>
<tbody>
<tr>
<td>P1</td>
<td>F</td>
<td>30</td>
<td>Cramps</td>
<td>68</td>
<td>AD</td>
<td>1 km</td>
<td>Age 68: sensorimotor</td>
<td>2–3x</td>
</tr>
<tr>
<td>P2</td>
<td>M</td>
<td>60</td>
<td>Cramps</td>
<td>82</td>
<td>Sporadic</td>
<td>Needs a walker</td>
<td>Age 79: sensorimotor (normal sural but reduced upper limb SNAPs)</td>
<td>2x</td>
</tr>
<tr>
<td>P3</td>
<td>M</td>
<td>70</td>
<td>Fasciculations</td>
<td>86</td>
<td>AD</td>
<td>Needs a walker</td>
<td>Age 82: sensorimotor (normal sural but reduced upper limb SNAPs)</td>
<td>2–3x</td>
</tr>
<tr>
<td>P4</td>
<td>M</td>
<td>25</td>
<td>Cramps</td>
<td>57</td>
<td>AD</td>
<td>Normal</td>
<td>Age 57: sensorimotor</td>
<td>2–3x</td>
</tr>
<tr>
<td>P5</td>
<td>F</td>
<td>46</td>
<td>Weakness</td>
<td>67</td>
<td>AD</td>
<td>Normal</td>
<td>Age 42: motor</td>
<td>Normal</td>
</tr>
<tr>
<td>P6</td>
<td>F</td>
<td>Before age 62</td>
<td>Cramps</td>
<td>66</td>
<td>AD</td>
<td>Normal</td>
<td>Age 66: sensorimotor</td>
<td>ND</td>
</tr>
<tr>
<td>P7</td>
<td>M</td>
<td>42</td>
<td>Weakness, fasciculations</td>
<td>44</td>
<td>AD</td>
<td>Normal</td>
<td>Motor</td>
<td>ND</td>
</tr>
<tr>
<td>P8</td>
<td>M</td>
<td>40</td>
<td>Weakness</td>
<td>55</td>
<td>AD</td>
<td>Normal</td>
<td>Sensorimotor</td>
<td>3x</td>
</tr>
<tr>
<td>P9</td>
<td>F</td>
<td>25</td>
<td>Cramps</td>
<td>37</td>
<td>AD</td>
<td>Normal</td>
<td>Motor</td>
<td>1.5x</td>
</tr>
<tr>
<td>P10</td>
<td>M</td>
<td>42</td>
<td>Weakness</td>
<td>49</td>
<td>Sporadic</td>
<td>Normal</td>
<td>Motor</td>
<td>ND</td>
</tr>
<tr>
<td>P11</td>
<td>F</td>
<td>40</td>
<td>Cramps</td>
<td>60</td>
<td>AD</td>
<td>Normal</td>
<td>Motor</td>
<td>ND</td>
</tr>
<tr>
<td>P12</td>
<td>F</td>
<td>28</td>
<td>Asymptomatic with absent tendon reflexes</td>
<td>52</td>
<td>AD</td>
<td>Normal</td>
<td>Age 28: sensorimotor</td>
<td>ND</td>
</tr>
<tr>
<td>P13</td>
<td>M</td>
<td>46</td>
<td>Myalgia</td>
<td>49</td>
<td>AD</td>
<td>Normal</td>
<td>Age 52: very little progression in sensory findings</td>
<td>3–6x</td>
</tr>
<tr>
<td>P14</td>
<td>F</td>
<td>Before age 42</td>
<td>Cramps</td>
<td>48</td>
<td>AD</td>
<td>Normal</td>
<td>Age 46: sensorimotor</td>
<td>2x</td>
</tr>
<tr>
<td>P15</td>
<td>F</td>
<td>Before age 60</td>
<td>Cramps</td>
<td>65</td>
<td>AD</td>
<td>Normal</td>
<td>Sensorimotor</td>
<td>2–3x</td>
</tr>
<tr>
<td>P16</td>
<td>F</td>
<td>54</td>
<td>Cramps</td>
<td>55</td>
<td>AD</td>
<td>Normal</td>
<td>Age 54: motor</td>
<td>1.5x</td>
</tr>
<tr>
<td>P17</td>
<td>M</td>
<td>46</td>
<td>Weakness</td>
<td>55</td>
<td>AD</td>
<td>Normal</td>
<td>Age 53: sensorimotor</td>
<td>2–3x</td>
</tr>
<tr>
<td>P18</td>
<td>F</td>
<td>39</td>
<td>Weakness and cramps</td>
<td>59</td>
<td>AD</td>
<td>Normal</td>
<td>Age 39: sensorimotor</td>
<td>2x</td>
</tr>
<tr>
<td>P19</td>
<td>F</td>
<td>Before age 64</td>
<td>Impaired walking/balance</td>
<td>70</td>
<td>AD</td>
<td>Walking sticks</td>
<td>Age 49: sensorimotor</td>
<td>ND</td>
</tr>
<tr>
<td>P20</td>
<td>F</td>
<td>Childhood?</td>
<td>Clumsiness in childhood, could be unrelated</td>
<td>60</td>
<td>AD</td>
<td>&lt;1 km</td>
<td>Age 67: motor</td>
<td>ND</td>
</tr>
<tr>
<td>P21</td>
<td>F</td>
<td>40</td>
<td>Cramps</td>
<td>58</td>
<td>AD</td>
<td>Normal</td>
<td>Age 60: sensorimotor</td>
<td>ND</td>
</tr>
<tr>
<td>P22</td>
<td>M</td>
<td>48</td>
<td>Weakness and fasciculations</td>
<td>51</td>
<td>Sporadic</td>
<td>Normal</td>
<td>Age 58: motor axonal</td>
<td>Normal</td>
</tr>
<tr>
<td>P23</td>
<td>F</td>
<td>58</td>
<td>Weakness</td>
<td>70</td>
<td>AD</td>
<td>Walking sticks</td>
<td>Age 51: sensorimotor</td>
<td>1.5–5x</td>
</tr>
</tbody>
</table>

**Notes:** AD, autosomal dominant; CK, creatine kinase; F, female; M, male; ND, not detected; SNAP, sensory nerve action potential.
inherited mutations in other genes that cause SMA may also cause CMT2. At least mutations in HSPB1, MFN2 and DYNC1H1 do not cause distinct entities but a continuum of phenotypes ranging from SMA to CMT2.\textsuperscript{20–22} As we have reported previously, SNAP reductions may occur in patients with SMAJ,\textsuperscript{5, 6} despite almost no clinical evidence of sensory dysfunction. In our experience, patients with SMAJ typically show clinical and/or EMG findings in a proximal and distal distribution already at the initial investigations, in contrast to CMT2, where disease progression to proximal muscles is a late phenomenon. In this respect, SMAJ is more similar to Kennedy CMT2, where disease progression to proximal muscles is a late phenomenon already at the initial investigations, in contrast to ALS,\textsuperscript{88, et al. J Neurol Neurosurg Psychiatry} where disease progression to proximal muscles is a late phenomenon already at the initial investigations, in contrast to SMAJ.\textsuperscript{5, 6} As the exon 2 are not included in variant databases due to low coverage of that area in exome sequences.\textsuperscript{16} As the quality and number of exome sequences increase, it is probable that many of the reported CHCHD10 variants appear to have some kind of frequency in a normal population making their pathogenic role more unlikely. Out of 11 CHCHD10 variants reported, at least 4 have received a frequency in the ExAC database (table 3), after the first reports of their possible pathogenicity. Since the population frequency seems to depend both on time and the population studied, it is not recommendable to call a variant pathogenic based on the population frequency alone.

Our results suggest that c.197G>T p.G66V is a common mutation in Finland, with 93 patients reported so far. In the SISu database V3.0 (http://www.sisuproject.fi) of 6104 Finnish individuals, c.197G>T p.G66V has been identified once. On the basis of the number of our determined patients and the SISu frequency, we estimate the prevalence of c.197G>T p.G66V to be around 2–4/100 000 in Finland. Other mutations in CHCHD10 are not common, at least not in the Finnish population. Our results also provide further evidence that pathogenic mutations in CHCHD10 are concentrated in exon 2, as previously reported (see table 3).\textsuperscript{12–15, 27}

So far, only three mutations in CHCHD10 have strong evidence for causality. Two of these, c.176C>T p.S59L and c.172G>C p.G58R, have been associated with mitochondrial myopathy and mtDNA instability.\textsuperscript{9, 10} CHCHD10 protein is part of the mitochondrial mitochondrial contact site and cristae organizing system (MICOS) complex, which is involved in cristae organization and thus mtDNA nucleoid maintenance.\textsuperscript{28} However, the patients carrying c.197G>T p.G66V have not presented signs of mitochondrial myopathy and mitochondrial pathologic has not been considerable in their muscle biopsies. In this study, we compared the amount of mtDNA deletions in 10 patients with SMAJ with 9 patients with other genetically defined MNDs. No significant increased amount of mtDNA deletions could be observed in the patients with SMAJ, supporting that mitochondrial pathology is not a feature of the SMAJ phenotype.

In general, CHCHD10-related disorders seem to be rare worldwide. So far, only three mutations causing three distinct

---

### Table 3  
Reported variants in CHCHD10

<table>
<thead>
<tr>
<th>Mutation</th>
<th>Exon</th>
<th>Frequency in ExAC</th>
<th>Reported phenotypes</th>
<th>Number of reported patients</th>
<th>Patient origin</th>
<th>Pathogenic according to functional studies</th>
<th>Segregates with the disease</th>
<th>Genomic frequency</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>c.34C&gt;T p.P12S</td>
<td>1</td>
<td>0.00001682</td>
<td>ALS</td>
<td>1</td>
<td>Spain</td>
<td>NA</td>
<td>NA</td>
<td>0.00000024</td>
<td>24</td>
</tr>
<tr>
<td>c.43C&gt;A p.R155*</td>
<td>2</td>
<td>–</td>
<td>MM</td>
<td>10</td>
<td>Puerto Rico</td>
<td>No</td>
<td>Yes</td>
<td>0.00000046</td>
<td>10</td>
</tr>
<tr>
<td>c.44C&gt;A p.R151L</td>
<td>2</td>
<td>–</td>
<td>ALS</td>
<td>13</td>
<td>Germany, USA, Canada</td>
<td>No</td>
<td>Nolyes</td>
<td>0.00000003</td>
<td>11, 13, 15, 26</td>
</tr>
<tr>
<td>c.67C&gt;A p.P23T</td>
<td>2</td>
<td>–</td>
<td>FTD</td>
<td>1</td>
<td>Italy</td>
<td>NA</td>
<td>NA</td>
<td>0.00000001</td>
<td>15</td>
</tr>
<tr>
<td>c.100C&gt;T p.P34S</td>
<td>2</td>
<td>0.0009654</td>
<td>ALS, FTD-ALS, PD, AD</td>
<td>15</td>
<td>France, Italy, Canada, Australia</td>
<td>NA</td>
<td>NA</td>
<td>0.00000001</td>
<td>12, 14–16, 27</td>
</tr>
<tr>
<td>c.104C&gt;A p.A35D</td>
<td>2</td>
<td>–</td>
<td>FTD</td>
<td>1</td>
<td>Italy</td>
<td>NA</td>
<td>NA</td>
<td>0.00000045</td>
<td>15</td>
</tr>
<tr>
<td>c.172G&gt;C p.G588*</td>
<td>2</td>
<td>–</td>
<td>MM</td>
<td>10</td>
<td>Puerto Rico</td>
<td>Yes</td>
<td>Yes</td>
<td>0.00000089</td>
<td>10</td>
</tr>
<tr>
<td>c.176C&gt;T p.S59L</td>
<td>2</td>
<td>–</td>
<td>FTD-ALS with MM</td>
<td>9</td>
<td>France, Spain</td>
<td>Yes</td>
<td>Yes</td>
<td>0.00000054</td>
<td>9, 12</td>
</tr>
<tr>
<td>c.197G&gt;T p.G66V</td>
<td>2</td>
<td>–</td>
<td>SMAJ, CMT2</td>
<td>73</td>
<td>Finland</td>
<td>NA</td>
<td>Yes</td>
<td>0.0000006</td>
<td>6, 8, 11, 23</td>
</tr>
<tr>
<td>c.239C&gt;T p.P80L</td>
<td>2</td>
<td>–</td>
<td>ALS</td>
<td>4</td>
<td>Italy, Canada</td>
<td>Possibly</td>
<td>Yes</td>
<td>0.00000002</td>
<td>14–15, 16, 27</td>
</tr>
<tr>
<td>c.244C&gt;T p.Q82X</td>
<td>2</td>
<td>0.00004243</td>
<td>FTD</td>
<td>1</td>
<td>Spain</td>
<td>NA</td>
<td>NA</td>
<td>0.00000002</td>
<td>24</td>
</tr>
</tbody>
</table>

\*Mutations in cis.

---

The variants have been annotated according to transcript NM_213720.

AD, Alzheimer’s disease; ALS, amyotrophic lateral sclerosis; CMT2, Charcot-Marie-Tooth disease type 2; FTD, frontotemporal dementia; FTD-ALS, frontotemporal lobar degeneration; MM, mitochondrial myopathy; NA, not assessed; PD, Parkinson’s disease; SMAJ, spinal muscular atrophy Jokela type.
Figure 2  Genealogical information of the patients with SMAJ found in this study. (A) Pedigrees of the patients related to other known patients with SMAJ. The patients reported previously have been marked with an asterisk. (B) Distribution of the patients with SMAJ (total 23) found in this study between Finnish hospital districts. SMAJ, spinal muscular atrophy Jokela type.

phenotypes have been reported, with other findings still requiring further evaluation (table 3). Of the ascertained CHCHD10-related disorders, SMAJ is by far the most frequent disease. This is at least in part due to the enrichment of the founder mutation in the genetically isolated Finnish population. Genealogical information of the patients with SMAJ found in this study was clarified retrospectively. Patient F3 was found to belong to a family reported by Pasanen et al. Patients P11 and P15 are sisters, as are patients P19 and P20 (figure A). No relations between other patients to each other or to the previously known families were found. However, owing to the founder effect of the c.197G>T p.G66V mutation in the Finnish population, it is evident that all Finnish patients carrying the mutation have a common ancestry, probably of Northern Karelian origin (figure B). The presence of SMAJ in other populations still needs further studies but, considering the large numbers of Finnish emigrants to different countries during the past 150 years, SMAJ should exist in some descendants. Furthermore, CHCHD10 mutations have mostly been evaluated in ALS cohorts and it is possible that CHCHD10 mutations are more prevalent in other disease types. Cohorts of patients with adult-onset lower MNDs, including Kennedy disease phenocopies, should be screened for CHCHD10 mutations.

Our results support the hypothesis that CHCHD10 mutations have a relatively strict genotype-phenotype correlation. However, more studies in different cohorts are definitely needed as well as further functional studies to elucidate how the different mutations result in the particular phenotypes.

Contributors  SP drafted the manuscript, acquired the data and performed the analysis. MJ, JP, JL and MA characterised the patients and edited the manuscript. AMS, JT and SS characterised the patients. MS acquired the data. EY and HT acquired the data and edited the manuscript. BU conceived the study, characterised the patients and edited the manuscript.

Competing interests  None declared.

Ethics approval  The local Ethical Committee of the University Hospital of Tampere and the local Ethical Committee of the University Hospital of Helsinki.

Provenance and peer review  Not commissioned; externally peer reviewed.

REFERENCES

Authors affiliations
1Neuromuscular Research Center, Tampere University Hospital and University Hospital, Tampere, Finland
2Division of Clinical Neurosciences, Turku University Hospital and University of Turku, Turku, Finland
3Department of Neurology, Central Hospital of Northern Karelia, Joensuu, Finland
4Department of Neurology, Seinäjoki Central Hospital, Seinäjoki, Finland
5Research Programs Unit, Molecular Neurology, University of Helsinki, Helsinki, Finland
6Department of Clinical Neurosciences, Neurology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
7Folkhalsan Institute of Genetics and Department of Medical Genetics, Haartman Institute, University of Helsinki, Helsinki, Finland
8Department of Neurology, Vasa Central Hospital, Vasa, Finland

Figure 2  Genealogical information of the patients with SMAJ found in this study. (A) Pedigrees of the patients related to other known patients with SMAJ. The patients reported previously have been marked with an asterisk. (B) Distribution of the patients with SMAJ (total 23) found in this study between Finnish hospital districts. SMAJ, spinal muscular atrophy Jokela type.


CHCHD10 mutations and motor neuron disease: the distribution in Finnish patients

Sini Penttilä, Manu Jokela, Anna Majaa Saukkonen, Jari Toivanen, Johanna Palmio, Janne Lähdesmäki, Satu Sandell, Mariia Shcherbii, Mari Auranen, Emil Ylikallio, Henna Tyynismaa and Bjarne Udd

J Neurol Neurosurg Psychiatry 2017 88: 272-277 originally published online November 3, 2016
doi: 10.1136/jnnp-2016-314154

Updated information and services can be found at:
http://jnnp.bmj.com/content/88/3/272

These include:

References
This article cites 28 articles, 11 of which you can access for free at:
http://jnnp.bmj.com/content/88/3/272#BBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

Motor neurone disease (302)
Neuromuscular disease (1311)
Drugs: CNS (not psychiatric) (1945)
Spinal cord (542)
Muscle disease (257)
Musculoskeletal syndromes (537)
Peripheral nerve disease (631)
Dementia (1020)
Memory disorders (psychiatry) (1390)
Radiology (1747)
Surgical diagnostic tests (401)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/